We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Seelos Therapeutics

News List

Seelos Announces Patent for SLS-007 americanpharmaceuticalreview
November 02, 2020
Seelos Therapeutics has been issued U.S. patent number 10815271 (application number 16/311,593) from the United States Patent and Trademark Office (USPTO) covering the composition of matter for SLS-007.
Seelos Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease americanpharmaceuticalreview
July 03, 2020
Seelos Therapeutics announced the initiation of a preclinical study of SLS-007 in Parkinson's disease (PD) delivered through an adeno associated viral (AAV) vector targeting the non-amyloid component core (NACore) of alpha synuclein (α-synuclein).
Seelos Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease americanpharmaceuticalreview
June 04, 2020
Seelos Therapeutics announced the initiation of a preclinical study of SLS-004 in Parkinson’s disease (PD) through an all-in-one lentiviral vector targeting the synuclein alpha (SNCA) gene.
Seelos Receives Rare Pediatric Disease Designation for Trehalose in Sanfilippo Syndrome americanpharmaceuticalreview
May 21, 2020
Seelos Therapeutics has been granted Rare Pediatric Disease Designation (RPDD) for SLS-005 in Sanfilippo syndrome from the U.S. Food and Drug Administration (FDA).